ABSTRACT
La malaria congénita es una patología relativamente rara en el contexto de las patologías neonatales. El presente caso se trata de un recién nacido masculino de 24 días de vida con malaria congénita por Plasmodium vivax y falciparum cuyo diagnóstico se observó a través del estudio de la gota gruesa. El recién nacido es procedente de una zona poco endémica, pero la madre viajó por compromiso laborales en varias ocasiones a una zona endémica en el Estado Bolívar. La madre presentó malaria gestacional a partir del I trimestre de gestación con tratamiento irregular. Las manifestaciones clínicas del recién nacido fueron fiebre de 40°c y el tratamiento antimalárico fue con Artesunate 60 mg con adecuada respuesta clínica, confirmada mediante la negativización de la gota gruesa al finalizar el tratamiento. Es importante considerar el diagnóstico diferencial con el de sepsis neonatal sobre todo en pacientes procedentes de zonas de riesgo y endémicas. La malaria congénita es real y por lo tanto se recomienda que los recién nacidos de madres con malaria deben ser examinados inmediatamente.
Congenital malaria is a relatively rare disease in the context of neonatal pathologies. We present a case of a 24 day old newborn male with congenital malaria by Plasmodium vivax and falciparum whose diagnosis was performed through the study of thick film. The newborn comes from a non- endemic area were as the mother because of worktravelled to an endemic area of our country in Bolivar state. The mother had a maternal history of seasonal malaria during the I trimester of gestation with irregular treatment. The clinical manifestation of the newborn was fever 40 °c and the antimalarial treatment was performed with Artesunate at 60 mg with adequate clinical response, confirmed by the thick film negativization at the end of the treatment. It is important to consider the differential diagnosis with neonatal sepsis especially in patients from endemic areas and risk. Congenital malaria is real and therefore it is recommended that newborns of mothers with malaria should be examined immediately.
ABSTRACT
INTRODUCTION: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient's symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases. OBJECTIVE: We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases. METHODS: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included. CONCLUSION: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.